255 related articles for article (PubMed ID: 35326549)
21. H3F3A K27M Mutations Drives a Repressive Transcriptome by Modulating Chromatin Accessibility, Independent of H3K27me3 in Diffuse Midline Glioma.
Bhattarai S; Hakkim FL; Day CA; Grigore F; Langfald A; Entin I; Hinchcliffe EH; Robinson JP
bioRxiv; 2024 May; ():. PubMed ID: 38798502
[TBL] [Abstract][Full Text] [Related]
22. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
[TBL] [Abstract][Full Text] [Related]
23. Diffuse Midline Gliomas With Histone H3 K27M Mutation in Adults and Children: A Retrospective Series of 164 Cases.
Zheng L; Gong J; Yu T; Zou Y; Zhang M; Nie L; Chen X; Yue Q; Liu Y; Mao Q; Zhou Q; Chen N
Am J Surg Pathol; 2022 Jun; 46(6):863-871. PubMed ID: 35416795
[TBL] [Abstract][Full Text] [Related]
24. Spinal Cord Diffuse Midline Glioma With Histone H3 K27M Mutation in a Pediatric Patient.
Cheng R; Li DP; Zhang N; Zhang JY; Zhang D; Liu TT; Yang J; Ge M
Front Surg; 2021; 8():616334. PubMed ID: 34222313
[No Abstract] [Full Text] [Related]
25. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
Vuong HG; Ngo TNM; Le HT; Dunn IF
J Neurooncol; 2022 Jul; 158(3):405-412. PubMed ID: 35606633
[TBL] [Abstract][Full Text] [Related]
26. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
[TBL] [Abstract][Full Text] [Related]
27. Radiologic findings and the molecular expression profile of diffuse midline glioma H3 K27M mutant.
Seong M; Kim ST; Noh JH; Kim YK; Kim HJ
Acta Radiol; 2021 Oct; 62(10):1404-1411. PubMed ID: 33175579
[TBL] [Abstract][Full Text] [Related]
28. Diffuse midline glioma H3 K27M-mutant in adults: A report of six cases and literature review.
Alzoubi H; Maraqa B; Hasasna N; Giangaspero F; Antonelli M; Gianno F; Arcella A; Al-Hussaini M
Clin Neuropathol; 2021; 40(2):108-117. PubMed ID: 33191898
[TBL] [Abstract][Full Text] [Related]
29. Imaging characteristics of adult H3 K27M-mutant gliomas.
Qiu T; Chanchotisatien A; Qin Z; Wu J; Du Z; Zhang X; Gong F; Yao Z; Chu S
J Neurosurg; 2019 Nov; 133(6):1662-1670. PubMed ID: 31731269
[TBL] [Abstract][Full Text] [Related]
30. Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis.
Mariet C; Castel D; Grill J; Saffroy R; Dangouloff-Ros V; Boddaert N; Llamas-Guttierrez F; Chappé C; Puget S; Hasty L; Chrétien F; Métais A; Varlet P; Tauziède-Espariat A
Acta Neuropathol Commun; 2022 Sep; 10(1):137. PubMed ID: 36104744
[TBL] [Abstract][Full Text] [Related]
31. Imaging characteristics of H3 K27M histone-mutant diffuse midline glioma in teenagers and adults.
Thust S; Micallef C; Okuchi S; Brandner S; Kumar A; Mankad K; Wastling S; Mancini L; Jäger HR; Shankar A
Quant Imaging Med Surg; 2021 Jan; 11(1):43-56. PubMed ID: 33392010
[TBL] [Abstract][Full Text] [Related]
32. Diffuse midline glioma with H3 K27M mutation: a comparison integrating the clinical, radiological, and molecular features between adult and pediatric patients.
Jiang H; Yang K; Ren X; Cui Y; Li M; Lei Y; Lin S
Neuro Oncol; 2020 May; 22(5):e1-e9. PubMed ID: 31504810
[TBL] [Abstract][Full Text] [Related]
33. Advanced MR imaging and
Piccardo A; Tortora D; Mascelli S; Severino M; Piatelli G; Consales A; Pescetto M; Biassoni V; Schiavello E; Massollo M; Verrico A; Milanaccio C; Garrè ML; Rossi A; Morana G
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1685-1694. PubMed ID: 31030232
[TBL] [Abstract][Full Text] [Related]
34. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M
Mount CW; Majzner RG; Sundaresh S; Arnold EP; Kadapakkam M; Haile S; Labanieh L; Hulleman E; Woo PJ; Rietberg SP; Vogel H; Monje M; Mackall CL
Nat Med; 2018 May; 24(5):572-579. PubMed ID: 29662203
[TBL] [Abstract][Full Text] [Related]
35. Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3 K27M Mutant Diffuse Midline Glioma.
Hohm A; Karremann M; Gielen GH; Pietsch T; Warmuth-Metz M; Vandergrift LA; Bison B; Stock A; Hoffmann M; Pham M; Kramm CM; Nowak J
Clin Neuroradiol; 2022 Mar; 32(1):249-258. PubMed ID: 34919158
[TBL] [Abstract][Full Text] [Related]
36. Radiotherapy and radio-sensitization in H3
Liu C; Kuang S; Wu L; Cheng Q; Gong X; Wu J; Zhang L
CNS Neurosci Ther; 2023 Jul; 29(7):1721-1737. PubMed ID: 37157237
[TBL] [Abstract][Full Text] [Related]
37. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
[No Abstract] [Full Text] [Related]
38. Extending the Neuroanatomic Territory of Diffuse Midline Glioma, K27M Mutant: Pineal Region Origin.
Gilbert AR; Zaky W; Gokden M; Fuller CE; Ocal E; Leeds NE; Fuller GN
Pediatr Neurosurg; 2018; 53(1):59-63. PubMed ID: 29131126
[TBL] [Abstract][Full Text] [Related]
39. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
[TBL] [Abstract][Full Text] [Related]
40. Pediatric spinal cord diffuse midline glioma, H3 K27-altered with intracranial and spinal leptomeningeal spread: A case report.
Serrallach BL; Tran BH; Bauer DF; Mohila CA; Adesina AM; McGovern SL; Lindsay HB; Huisman TA
Neuroradiol J; 2022 Oct; 35(5):634-639. PubMed ID: 34989626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
